Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Hasan Mohidat

Ophthalmology Houston, TX Medical Doctor

NPI 1295490720 CMS profile 11257936

4704 Montrose Blvd, Houston, TX 77006

Open in the dashboard

General payments

$3,806

54 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hasan Mohidat of Houston, TX is reported in the CMS Open Payments database as having received $3,806 across 54 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $611 11
2024 General $2,531 32
2023 General $620 9
2022 General $44 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hasan Mohidat
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Hasan Mohidat were reported at $611. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Hasan Mohidat Ophthalmology median Middle half National median
2019 $0 $258 $104–$655 $163
2020 $0 $126 $45–$321 $114
2021 $0 $205 $76–$534 $132
2022 $44 $266 $100–$678 $149
2023 $620 $308 $117–$745 $160
2024 $2,531 $340 $127–$846 $164
2025 $611 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Bausch & Lomb Americas Inc. $1,573 15 payments
  2. Regeneron Healthcare Solutions, Inc. $698 8 payments
  3. Astellas Pharma US Inc $433 5 payments
  4. Johnson & Johnson Surgical Vision, Inc. $244 3 payments
  5. Genentech USA, Inc. $156 6 payments
  6. Tarsus Pharmaceuticals, Inc. $140 5 payments
  7. TissueTech, Inc. $126 1 payment
  8. Rayner Intraocular Lenses Limited $112 1 payment
  9. Genentech, Inc. $93 1 payment
  10. Alcon Vision LLC $73 3 payments
  11. Other $157 6 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,912 49 payments
  2. Travel and Lodging $893 5 payments
Products named General payments · program years 2022–2025
  1. enVista Aspire IOL $1,312 12 payments
  2. STELLARIS ELITE $1,312 12 payments
  3. TENEO $1,312 12 payments
  4. EYLEA HD $543 5 payments
  5. Izervay $283 3 payments
  6. VABYSMO $250 7 payments
  7. CATALYS SYSTEM $157 2 payments
  8. EYLEA $155 3 payments
  9. XDEMVY $140 5 payments
  10. STELLARIS $131 1 payment
  11. Other $1,221 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

2,787

Median for Ophthalmology: 891

Drug cost

$240,265

Median for Ophthalmology: $68,233

Branded share of claims

18.6%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 58 $72,406
Lumigan Bimatoprost Brand 112 $47,811
Prednisolone Acetate Generic 494 $21,022
Rhopressa Netarsudil Mesylate Brand 23 $15,728
Combigan Brimonidine Tartrate/Timolol Brand 32 $15,626
Rocklatan Netarsudil Mesylat/Latanoprost Brand 17 $12,751
Latanoprost Generic 694 $8,431
Cyclosporine Generic 13 $7,756
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 24 $5,123
Alphagan P Brimonidine Tartrate Brand 13 $5,005

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$106,694

Of which drugs: $32,022

Medicare patients

219

Average age 74

Services billed

1,165

116 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 55%
Arthritis 42%
Ischemic heart disease 38%
Chronic kidney disease 37%
Heart failure 21%
Depression 16%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, bevacizumab, 10 mg J9035 Office 19 45 $2,500

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $245
$245 — —
Izervay
  • Astellas Pharma US Inc $158
$158 — —
VABYSMO
  • Genentech, Inc. $93
  • Genentech USA, Inc. $53
$147 — —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $33
$33 — —
OZURDEX
  • AbbVie, Inc. $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

54 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record